In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma

Journal of Immunology

Volumn 164, Issue 6, 2000, Pages 3402-3412

  Linette, Gerald P ^a   Shankara, Srinivas ^c   Longerich, Simonne ^a   Yang, Sixun ^a   Doll, Rhonda ^c   Nicolette, Charles ^c   Preffer, Frederic I ^a,b   Roberts, Bruce L ^c   Haluska, Frank G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Genzyme Molecular Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 100; HLA A ANTIGEN;

ADENOVIRUS; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; DENDRITIC CELL; DRUG EFFECT; ENHANCER REGION; EPITOPE MAPPING; GENE TRANSFER; HELPER CELL; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0034653475     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.6.3402     Document Type: Article

References (56)

1. Reddy, A., M. Sapp, M. Feldman, M. Subklewe, and N. Bhardwaj. 1997. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90:3640.
2. Caux, C., C. Massacrier, B. Vanbervlit, B. Dubois, C. Van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.
3. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.
4. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109.
5. + cytolytic T cell responses. J. Exp. Med. 182:1663.
6. Steinman, R. 1999. Dendritic cells. In Fundamental Immunology, 4th Ed. W.E. Paul, ed. Lippincott-Raven, Philadelphia, 547 pp.
7. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
8. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
9. Zitvogel, L., J. I. Maayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
10. Song, W., H.-L. Kong, H. Carpenter, H. Turii, R. Granstein, S. Rafii, M. Moore, and R. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model tumor antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247.
11. Toes, R., E. van der Voort, S. Schoenberger, J. Drijfhout, L. van Bloonis, G. Storm, W. Kast, R. Offringa, and C. Melief. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160:4449.
12. Kaplan, J., Q. Yu, S. Piraino, S. Pennington, S. Shankara, L. Woodworth, and B. Roberts. 1999. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163:699.
13. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, and M. T. Lotze, T. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
14. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
15. Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371.
16. Nestle, F., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
17. Dietz, A., and S. Vuk-Pavlovic. 1998. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91:392.
18. Butterfield, L. H., S. M. Jilani, N. G. Chakraborty, L. A. Bui, A. Ribas, V. B. Dissette, R. Lau, S. Gamradt, J. A. Glaspy, W. H. McBride, et al. 1998. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161:5607.
19. Zhong, L., A. Granelli-Piperno, Y. Choi, and R. Steinman. 1999. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:964.
20. Hehir, K., D. Armentano, L. Cardoza, T. Choquette, P. Berthelette, G. White, L. Couture, M. Everton, J. Keegan, J. Martin, et al. 1996. Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. J. Virol. 70:8459.
21. Armentano, D., J. Zabner, C. Sacks, C. Sookdeo, M. Smith, J. St. George, S. Wadsworth, A. Smith, and R. Gregory. 1997. Effect of the E4 region on the persistence of transgcne expression from adenovirus vector. J. Virol. 71:2408.
22. Yang, Y., F. Nunes, K. Berencsi, E. Furth, M. Gonczol, and J. Wilson. 1994. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407.
23. Rosenberg, S., Y. Zhai, J. Yang, D. Schwartzentruber, P. Hwu, F. Marincola, S. Topalian, N. Reslito, C. Seipp, J. Einhorn, et al. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1894.
24. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18:267.
25. Cormier, J., A. Abati, P. Fetsch, Y. Hijazi, S. Rosenberg, F. Marincola, and S. Topalian. 1998. Comparative analysis of the in vivo expression of tyrosinase. Mart-1/Melan-A, and gp100 in metastatic melanoma lesions: implications lor immunotherapy. J. Immunother. 21:27.
26. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. Robbins, A. Sette, E. Appella, and S. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
27. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. 1997. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158:1796.
28. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
29. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethe, P. Romero, T. Boon, and J.-C. Renauld. 1996. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pme117/gp100. J. Invest. Dermatol. 107:63.
30. Zhai, Y., J. C. Yang, Y. Kawakami, P. Spiess, S. C. Wadsworth, L. M. Cardoza, L. A. Couture, A. E. Smith, and S. A. Rosenberg. 1996. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J. Immunol. 156:7090.
31. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356:443.
32. Parham, P., and F. M. Brodsky. 1981. Partial purification and some properties of BB7.2, a cytotoxic monoclonal antibody with specificity for HLA-A2 and variant HLA-A28. Hum. Immunol. 3:277.
33. Bender, A., M. Sapp, G. Schuler, R. M. Steinman, and N. Bhardwaj. 1996. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196:121.
34. Chroboczek, J., and B. Jacrot. 1987. The sequence of adenovirus fiber: similarities and differences between serotypes 2 and 5, Virology 161:549.
35. Leopold, P., B. Ferris, I. Grinberg, S. Worgall, N. Hackett, and R. Crystal. 1998. Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum. Gene Ther. 9:367.
36. Darrow, T., C. Slingluff, and H. Seigler. 1989. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J. Immunol. 142:3329.
37. Banchereau, J., and R. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
38. Bergelson, J., J. Cunningham, G. Drogette, F. Kurt-Jones, A. Krithivas, J. Hong, M. Horwitz, R. Crowell, and R. Finberg. 1997. Isolation of a common receptor tor coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320.
39. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. M. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
40. Bertoni, R., J. Sidney, P. Fowler, R. Chesnut, F. Chisari, and A. Sette. 1997. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J. Clin. Invest. 100:503.
41. Ribas, A., L. Butterfield, W. McBride, S. Jilani, L. Bui, C. Vollmer, R. Lau, V. Dissette, B. Hu, A. Chen, et al. 1997. Genetic immunization for the melanoma antigen MART1/Melan-A using recombinant adenovirus transduced murine dendritic cells. Cancer Res. 57:2865.
42. Sallusto, F., P. Schaerli, P. Loetscher, C. Schaniel, D. Lenig, C. Mackay, S. Qin, and A. Lanzavecchia. 1998. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28:2760.
43. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines. J. Exp. Med 182:389.
44. Albert, M., S. Pearce, L. Francisco, B. Sauter, P. Roy, R. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via αv-β5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359.
45. Wickham, T., P. Mathias, D. Cheresh, and G. Nemerow. 1993. Integrins promote adenovirus internalization but not virus attachment. Cell 73:309.
46. DiNicola, M., S. Siena, M. Bregni, P. Longoni, M. Magni, M. Milanesi, P. Matteucci, R. Mortarini, A. Anichini, G. Parmiani, et al. 1998. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors. Cancer Gene Ther. 5:350.
47. Zabner, J., P. Freimuth, A. Puga, A. Fabrega, and M. Welsh. 1997. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J. Clin. Invest. 100:1144.
48. Hidaka, C., E. Milano, P. Leopold, J. Bergelson, N. Hackett, R. Finberg, T. Wickham, I. Kovesdi, P. Roelvink, and R. Crystal. 1999. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 103:579.
49. Walters, R., T. Grunst, J. Bergelson, R. Finberg, M. Welsh, and J. Zabner. 1999. Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J. Biol. Chem. 274:10219.
50. Hemmi, S., R. Geertsen, A. Mezzacasa, I. Peter, and R. Dummer. 1998. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum. Gene Ther. 9:2363.
51. Steinman, R. M., and J. Swanson. 1995. The endocytic activity of dendritic cells. J. Exp. Med. 182:283.
52. Pardoll, D. 1999. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96:5340.
53. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749.
54. Shimizu, Y., L. Guidotti, P. Fowler, and F. Chisari. 1998. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161:4520.
55. Dittel, B., I. Visintin, R. Merchant, and C. Janeway, Jr. 1999. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol. 163:32.
56. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163.